Impact of age on genetics and treatment efficacy in follicular lymphoma

被引：12

作者：

Alig, Stefan ^{[1
]}

Jurinovic, Vindi ^{[1
,2
]}

Pastore, Alessandro ^{[3
]}

Bararia, Deepak ^{[1
]}

Haebe, Sarah ^{[1
]}

Hellmuth, Johannes C. ^{[1
,4
]}

Kridel, Robert ^{[5
]}

Gascoyne, Randy ^{[6
,7
]}

Schmidt, Christian ^{[1
]}

Zoellner, Anna-Katharina ^{[1
]}

Buske, Christian ^{[8
]}

Dreyling, Martin ^{[1
]}

Unterhalt, Michael ^{[1
]}

Hiddemann, Wolfgang ^{[1
,9
,10
]}

Hoster, Eva ^{[1
,2
]}

Weigert, Oliver ^{[1
,9
,10
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Inst Med Informat Biometry & Epidemiol, Munich, Germany

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Weill Cornell Med, Dept Med, Div Hematol & Med Oncol, New York, NY USA

[5] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[6] BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada

[7] BC Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC, Canada

[8] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany

[9] German Canc Consortium DKTK, Munich, Germany

[10] German Canc Res Ctr, Heidelberg, Germany

来源：

HAEMATOLOGICA | 2018年 / 103卷 / 08期

关键词：

1ST-LINE TREATMENT; DISEASE CHARACTERISTICS; TREATMENT PATTERNS; RITUXIMAB; MUTATIONS; INDOLENT; OUTCOMES; TRIAL; CHOP;

D O I：

10.3324/haematol.2018.187773

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E364 / E367

页数：4

共 15 条

[1] Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion [J].

Bar, Merav ;

Flowers, Mary ;

Storer, Barry E. ;

Chauncey, Thomas R. ;

Pulsipher, Michael A. ;

Thakar, Monica S. ;

Bethge, Wolfgang ;

Storb, Rainer F. ;

Maloney, David G. ;

Sandmaier, Brenda M. .

BLOOD, 2016, 128 (22)

[2] Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study [J].

Casulo, C. ;

Day, B. ;

Dawson, K. L. ;

Zhou, X. ;

Flowers, C. R. ;

Farber, C. M. ;

Hainsworth, J. D. ;

Cerhan, J. R. ;

Link, B. K. ;

Zelenetz, A. D. ;

Friedberg, J. W. .

ANNALS OF ONCOLOGY, 2015, 26 (11) :2311-2317

[3] Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project [J].

Federico, Massimo ;

Bellei, Monica ;

Marcheselli, Luigi ;

Luminari, Stefano ;

Lopez-Guillermo, Armando ;

Vitolo, Umberto ;

Pro, Barbara ;

Pileri, Stefano ;

Pulsoni, Alessandro ;

Soubeyran, Pierre ;

Cortelazzo, Sergio ;

Martinelli, Giovanni ;

Martelli, Maurizio ;

Rigacci, Luigi ;

Arcaini, Luca ;

Di Raimondo, Francesco ;

Merli, Francesco ;

Sabattini, Elena ;

McLaughlin, Peter ;

Solal-Celigny, Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4555-4562

[4] Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study [J].

Flinn, Ian W. ;

van der Jagt, Richard ;

Kahl, Brad S. ;

Wood, Peter ;

Hawkins, Tim E. ;

MacDonald, David ;

Hertzberg, Mark ;

Kwan, Yiu-Lam ;

Simpson, David ;

Craig, Michael ;

Kolibaba, Kathryn ;

Issa, Samar ;

Clementi, Regina ;

Hallman, Doreen M. ;

Munteanu, Mihaela ;

Chen, Ling ;

Burke, John M. .

BLOOD, 2014, 123 (19) :2944-2952

[5] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[6] Obinutuzumab for the First-Line Treatment of Follicular Lymphoma [J].

Marcus, R. ;

Davies, A. ;

Ando, K. ;

Klapper, W. ;

Opat, S. ;

Owen, C. ;

Phillips, E. ;

Sangha, R. ;

Schlag, R. ;

Seymour, J. F. ;

Townsend, W. ;

Trneny, M. ;

Wenger, M. ;

Fingerle-Rowson, G. ;

Rufibach, K. ;

Moore, T. ;

Herold, M. ;

Hiddemann, W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14) :1331-1344

[7] Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. [J].

Murawski, Niels ;

Miriam, Josif ;

Altmann, Bettina ;

Ziepert, Marita ;

Haenel, Mathias ;

Viardot, Andreas ;

Neubauer, Andreas ;

Held, Gerhard ;

Truemper, Lorenz ;

Schmidt, Christian ;

Kanz, Lothar ;

Hallek, Michael ;

Schmitz, Norbert ;

Heintges, Tobias ;

Koelbel, Christian ;

Poeschel, Viola ;

Pfreundschuh, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[8] Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States [J].

Nabhan, Chadi ;

Byrtek, Michelle ;

Rai, Ashish ;

Dawson, Keith ;

Zhou, Xiaolei ;

Link, Brian K. ;

Friedberg, Jonathan W. ;

Zelenetz, Andrew D. ;

Maurer, Matthew J. ;

Cerhan, James R. ;

Flowers, Christopher R. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) :85-95

[9] Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry [J].

Pastore, Alessandro ;

Jurinovic, Vindi ;

Kridel, Robert ;

Hoster, Eva ;

Staiger, Annette M. ;

Szczepanowski, Monika ;

Pott, Christiane ;

Kopp, Nadja ;

Murakami, Mark ;

Horn, Heike ;

Leich, Ellen ;

Moccia, Alden A. ;

Mottok, Anja ;

Sunkavalli, Ashwini ;

Van Hummelen, Paul ;

Ducar, Matthew ;

Ennishi, Daisuke ;

Shulha, Hennady P. ;

Hother, Christoffer ;

Connors, Joseph M. ;

Sehn, Laurie H. ;

Dreyling, Martin ;

Neuberg, Donna ;

Moeller, Peter ;

Feller, Alfred C. ;

Hansmann, Martin L. ;

Stein, Harald ;

Rosenwald, Andreas ;

Ott, German ;

Klapper, Wolfram ;

Unterhalt, Michael ;

Hiddemann, Wolfgang ;

Gascoyne, Randy D. ;

Weinstock, David M. ;

Weigert, Oliver .

LANCET ONCOLOGY, 2015, 16 (09) :1111-1122

[10] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [J].

Rummel, Mathias J. ;

Niederle, Norbert ;

Maschmeyer, Georg ;

Banat, G. Andre ;

von Gruenhagen, Ulrich ;

Losem, Christoph ;

Kofahl-Krause, Dorothea ;

Heil, Gerhard ;

Welslau, Manfred ;

Balser, Christina ;

Kaiser, Ulrich ;

Weidmann, Eckhart ;

Duerk, Heinz ;

Ballo, Harald ;

Stauch, Martina ;

Roller, Fritz ;

Barth, Juergen ;

Hoelzer, Dieter ;

Hinke, Axel ;

Brugger, Wolfram .

LANCET, 2013, 381 (9873) :1203-1210

← 1 2 →